These forward-looking statements include statements regarding substantially lower cash expenditures for the second half of 2011 and increased expenditures in 2012, the protocol for, and the timing and feasibility of, the CVOT
, the initiation of enrollment for the CVOT
in the first half of 2012 and the engagement of a clinical research organization, a clear and feasible path forward for Contrave, and the potential for, and timing of, approval for Contrave.
According to the Company, 12 Advisory Committee members voted to not require cardiovascular outcomes trials (CVOTs
) for PAMORAS, seven members voted to require CVOTs
for all PAMORAS, and five members voted to require CVOTs
, but only for specific PAMORAS.